Thymosin Beta-4

Thymosin Beta-4 Investigational Compounded

Also known as: TB4, Tβ4
Category: Tissue Repair & Recovery — Endogenous Regenerative Protein

What it actually is—and why the name confusion matters. Thymosin Beta-4 is a naturally occurring 43-amino-acid protein present in nearly every human cell except red blood cells. It was first isolated from calf thymus, which is where the name comes from, though it turned out to be nearly ubiquitous in the body. It is not the same thing as TB-500, which is a much shorter synthetic fragment. Patients and clinics use the two names interchangeably constantly. They shouldn't—different molecules, different pharmacokinetics, different evidence bases, and different regulatory considerations. That is exactly why we give each its own page.

How it works. TB4's best-characterized biochemical role is regulating actin—the cytoskeletal protein cells use to change shape and migrate—by sequestering monomeric G-actin. That single mechanism sits underneath most of what the literature explores: cell migration into injured tissue, angiogenesis (new blood vessel formation), anti-inflammatory signaling, and cytoprotection. In healthy bodies, TB4 levels rise naturally after injury to help orchestrate repair. Animal studies from the 1990s onward demonstrated that TB4 promotes tissue repair in skin and increases blood supply to damaged tissue.

Why a physician might discuss it, and honest expectations. Full-length TB4 carries the more substantial human research record of the two forms, including the RegeneRx Biopharmaceuticals clinical program in topical and ophthalmic wound healing—corneal repair, dry eye, and dermal wounds—plus cardiac studies following ischemic injury. That human safety context is real, and it is more than most repair peptides can claim. What it does not do is validate injectable use for general soft-tissue repair, which remains investigational. TB4 is not FDA-approved for human use and is on the World Anti-Doping Agency prohibited list at all times. Because pro-migratory and pro-angiogenic effects could theoretically support occult tumor growth, cancer history matters. Effects, when reported, develop gradually over weeks—this is not a painkiller, and it is not a reason to postpone imaging, physical therapy, or surgical evaluation.